KyndrisaChristopher Marai

Last Friday, the FDA released briefing documents for a BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) meeting regarding drisapersen (Kyndrisa) scheduled to take place on Tuesday; the documents focused on efficacy concerns and dystrophin data. In a report issued Friday, Oppenheimer analysts assured...